8-K
filed March 26, 2026, 7:59 PM ET
ticker ENTA
CIK 0001177648
litigation
confidence high
sentiment neutral
materiality 0.40
Federal Circuit schedules May 11, 2026 oral argument for Enanta's patent appeal against Pfizer over Paxlovid
ENANTA PHARMACEUTICALS INC
- Federal Circuit oral argument in Enanta's patent appeal against Pfizer (Paxlovid) set for May 11, 2026.
- Enanta originally filed suit for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
- Notice of appeal was filed on February 3, 2025.
- The appeal is before the U.S. Court of Appeals for the Federal Circuit.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-125113
- form_type
- 8-K
- ticker
- ENTA
- cik
- 0001177648
- company_name
- ENANTA PHARMACEUTICALS INC
- filed_at
- 2026-03-26T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:34.645985+00:00
- generated_at
- 2026-05-15T08:47:06.626818+00:00
- sec_items
- ["8.01"]
- event_type
- litigation
- sentiment
- neutral
- materiality_score
- 0.4
- calibrated_materiality_score
- 0.4
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-125113
- json_url
- https://secwatch.observer/filing/0001193125-26-125113.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-125113.md
- text_url
- https://secwatch.observer/filing/0001193125-26-125113.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/0001193125-26-125113-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/enta-20260320.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
OLPX
Olaplex settles derivative suit with $700K in fees and governance reforms; court preliminarily approves
OLAPLEX HOLDINGS, INC.
May 29, 2026, 4:17 PM ET
litigation
Items 8.01, 9.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
MCFT
MasterCraft settles stockholder lawsuit over director removal provision; pays $425k in fees
MasterCraft Boat Holdings, Inc.
May 22, 2026, 8:30 AM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
NUWE
Nuwellis settles E.F. Hutton lawsuit for $204K; mutual release, dismissal with prejudice
Nuwellis, Inc.
April 24, 2026, 7:59 PM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
ANGO
AngioDynamics files patent infringement suit against Endovascular Engineering over Hēlo Thrombectomy System
ANGIODYNAMICS INC
April 23, 2026, 7:59 PM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
NEXT-ChemX Corporation.
NEXT-ChemX dismisses lawsuit against Sparkie Properties; Texas appeals court rules in favor of Sparkie
NEXT-ChemX Corporation.
April 20, 2026, 7:59 PM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
MSTR
Strategy settles STRK preferred lawsuit; pays $550K fees, holds 762K BTC
Strategy Inc
March 30, 2026, 7:59 PM ET
litigation
Items 8.01, 7.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
CPRX
Catalyst bench trial for FIRDAPSE patents delayed from March 23 to May 18, 2026
CATALYST PHARMACEUTICALS, INC.
March 18, 2026, 7:59 PM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
DFNS
T3 Defense sued by Kingswood Capital over alleged success fee; company denies claims
T3 Defense Inc.
March 6, 2026, 6:59 PM ET
litigation
Items 8.01
same SEC item: 8.01
same event type: litigation
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.